Matthew Taylor

Summary

Affiliation: University of York
Country: UK

Publications

  1. ncbi Pharmacoeconomic benefits of dasatinib in the treatment of imatinib-resistant patients with chronic myelogenous leukemia
    Matthew J Taylor
    York Health Economics Consortium Ltd, Market Square, University of York, York, YO10 5NH, UK
    Expert Rev Pharmacoecon Outcomes Res 9:117-21. 2009
  2. ncbi Acute coronary syndromes in Europe: 1-year costs and outcomes
    Matthew J Taylor
    York Health Economics Consortium Ltd, University of York, UK
    Curr Med Res Opin 23:495-503. 2007
  3. ncbi An economic evaluation of sevelamer in patients new to dialysis
    Matthew J Taylor
    York Health Economics Consortium Ltd, University of York, UK
    Curr Med Res Opin 24:601-8. 2008
  4. ncbi An economic evaluation of valsartan for post-MI patients in the UK who are not suitable for treatment with ACE inhibitors
    Matthew Taylor
    University of York, York Health Economics Consortium, York, UK
    Value Health 12:459-65. 2009
  5. ncbi The cost of needlestick injuries associated with insulin administration
    Paul Trueman
    York Economics Consortium, Novo Nordisk, Crawley
    Br J Community Nurs 13:413-7. 2008

Detail Information

Publications5

  1. ncbi Pharmacoeconomic benefits of dasatinib in the treatment of imatinib-resistant patients with chronic myelogenous leukemia
    Matthew J Taylor
    York Health Economics Consortium Ltd, Market Square, University of York, York, YO10 5NH, UK
    Expert Rev Pharmacoecon Outcomes Res 9:117-21. 2009
    ..Dasatinib is associated with higher levels of response compared with high-dose imatinib. In addition, higher levels of response are associated with improved health outcomes in terms of both quality- and quantity-of-life years...
  2. ncbi Acute coronary syndromes in Europe: 1-year costs and outcomes
    Matthew J Taylor
    York Health Economics Consortium Ltd, University of York, UK
    Curr Med Res Opin 23:495-503. 2007
    ..This study aims to estimate costs (including medications prescribed, intervention rates and hospital utilization) and health outcomes of acute coronary syndromes (ACS) during the first year following diagnosis...
  3. ncbi An economic evaluation of sevelamer in patients new to dialysis
    Matthew J Taylor
    York Health Economics Consortium Ltd, University of York, UK
    Curr Med Res Opin 24:601-8. 2008
    ..The overall objective of this study was to estimate the costs and outcomes associated with treatment with sevelamer for hyperphosphataemia compared with calcium-based binders...
  4. ncbi An economic evaluation of valsartan for post-MI patients in the UK who are not suitable for treatment with ACE inhibitors
    Matthew Taylor
    University of York, York Health Economics Consortium, York, UK
    Value Health 12:459-65. 2009
    ....
  5. ncbi The cost of needlestick injuries associated with insulin administration
    Paul Trueman
    York Economics Consortium, Novo Nordisk, Crawley
    Br J Community Nurs 13:413-7. 2008
    ..Trusts are encouraged to implement improved monitoring and surveillance procedures to inform the debate on the appropriate use of safety devices...